Inhaled Antibiotics Market Size and Trends

Inhaled Antibiotics MarketSize and Trends

The global Inhaled antibiotics market is estimated to be valued at US$ 1,403.3 Million in 2023 and is expected to exhibit a CAGR of 6.7% during the forecast period (2023-2030).

Investments in the development of inhaled antibiotics are a key trend gaining popularity in inhaled antibiotics market. Major pharmaceutical companies are investing in the development of inhaled antibiotics to sustain its position in the market.

Global Inhaled Antibiotics Market Trends

Global Inhaled Antibiotics Market has gained momentum in recent times because of the increasing incidence of chronic respiratory disorders such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis. Furthermore, an increase in research and development and company initiatives are the factors for the growth of the inhaled antibiotics which shows significant opportunities for global Inhaled Antibiotics Market growth over the forecast period.

Growing geriatric population

Growing geriatric population can also drive the inhaled antibiotics market growth. For instance, according to an article published in World Health Orgnisation, in November 2022, reported 1 in 6 people in the world will be aged 60 years or over. At this time the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion).

Inhaled Antibiotics Market Report Coverage

Forecast Period:2023 to 2030Forecast Period 2023 to 2030 CAGR:6.7%

Market- Trends

Among all the segmentations, the product type has the potential due to the increasing respiratory tract infection this is expected to drive the growth of the segment over the forecast period. For instance, in April 2022, according to the World Health Organization (WHO), reported respiratory infections account for 6% of the total global disease burden. Around 6.6 million, under-five aged children years of age die each year worldwide; 95 percent of them belong to low-income countries and one third of the total deaths is due to acute respiratory track infection.